SCHEMBL308400

SCHEMBL308400

Cn1ccnc1-c1nccn1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPO P22079 1/20 0.55
BRD4 O60885 1/20 0.47
KDM4E B2RXH2 3/20 0.44
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
RAB9A P51151 1/20 0.44
HSD17B10 Q99714 2/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTT P42858 1/20 0.38
FDPS P14324 2/20 0.36
HDAC4 P56524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31153305 0.97 LPO (0.52) LPOBRD4KDM4ENPC1PKM
Hydrochloric Acid SCHEMBL1806963 0.97 LPO (0.52) LPOBRD4KDM4ENPC1PKM
SCHEMBL30420079 0.89 LPO (0.46) LPOBRD4KDM4ENPC1PKM
SCHEMBL171888 0.85 LPO (0.43) LPOBRD4KDM4ENPC1PKM
SCHEMBL13052883 0.84 LPO (0.46) LPOBRD4KDM4ENPC1PKM
SCHEMBL23370195 0.82 KDM4E (0.46) LPOBRD4KDM4ENPC1PKM
SCHEMBL2936291 0.82 ALDH1A1 (0.46) LPOBRD4KDM4ENPC1PKM
SCHEMBL16510053 0.82 LPO (0.40) LPOBRD4KDM4ENPC1PKM
SCHEMBL1926651 0.80 LPO (0.39) LPOBRD4KDM4ENPC1PKM
SCHEMBL15149 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119303568-A High-dispersity palladium-carbon catalyst and preparation method thereof 长春黄金研究院烟台贵金属材料研究所有限公司 2025-01-14 CN claimed
CN-117736456-A Hyperbranched structure redox polymer, glucose sensing material, and preparation method and application thereof 江苏鱼跃凯立特生物科技有限公司 2024-03-22 CN claimed
CN-116135868-A Method for heteroaryl treatment of eighth main group metallocene compound 中国科学院大连化学物理研究所 2023-05-19 CN claimed
CN-115856050-A Preparation method of monatomic glucose electrochemical working electrode 民康医疗科技(天津)有限公司 2023-03-28 CN claimed
CN-122011354-A Biimidazole catalyst for liquid crystal polyarylester synthesis and application thereof 浙江海利得科技有限公司 2026-05-12 CN disclosed
US-20250368670-A1 TRANSITION METAL COMPLEX AND METHODS FOR ITS PREPARATION AND USE SHANGHAI UNITED IMAGING MICROELECTRONICS TECH CO LTD (CN) 2025-12-04 US disclosed
US-20250369916-A1 ELECTROCHEMICAL BIOSENSOR, PREPARATION METHOD, AND USE SHANGHAI UNITED IMAGING MICROELECTRONICS TECH CO LTD (CN) 2025-12-04 US disclosed
EP-4656647-A1 TRANSITION METAL COMPLEX AND METHODS FOR ITS PREPARATION AND USE Shanghai United Imaging Microelectronics Technology Co., Ltd. (CN) 2025-12-03 EP disclosed
EP-4656733-A1 ELECTROCHEMICAL BIOSENSOR, PREPARATION METHOD, AND USE Shanghai United Imaging Microelectronics Technology Co., Ltd. (CN) 2025-12-03 EP disclosed
US-20250194964-A1 GLUCOSE OXIDASE SENSORS WITH IMPROVED STABILITY ABBOTT DIABETES CARE, INC. 2025-06-19 US disclosed
WO-2025040753-A1 ELECTROCHEMICAL IMMUNOASSAY ROCHE DIAGNOSTICS GMBH (DE) 2025-02-27 WO disclosed
CN-119303568-A High-dispersity palladium-carbon catalyst and preparation method thereof 长春黄金研究院烟台贵金属材料研究所有限公司 2025-01-14 CN disclosed
US-20070007132-A1 Transition metal complexes with bidentate ligand having an imidazole ring ABBOTT DIABETES CARE INC. 2007-01-11 US disclosed
US-7090756-B2 Controller for redox system THERASENSE INC. (US) 2006-08-15 US disclosed
EP-1230249-B1 TRANSITION METAL COMPLEXES WITH BIDENTATE LIGAND HAVING AN IMIDAZOLE RING THERASENSE INC (US) 2004-06-02 EP disclosed
US-20040040840-A1 Controller for redox system THERASENSE, INC. 2004-03-04 US disclosed
US-6605200-B1 Charge transfer compounds comprising polymers such as polyvinylpyridine and/or copolymers coupled to osmium compounds, used as biosensors in redox systems THERASENSE, INC. 2003-08-12 US disclosed
US-6605201-B1 Charge transfer compounds comprising osmium compounds coupled to polymers, used as biosensors THERASENSE, INC. 2003-08-12 US disclosed
EP-1230248-A2 TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN Therasense, Inc. (US) 2002-08-14 EP disclosed
WO-2001036660-A2 TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN THERASENSE, INC. (US) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040040840-A1 Controller for redox system OTC, ME3, PPOX LPO 29/4885BRD4 696/4885KDM4E 1472/4885
US-20250368670-A1 TRANSITION METAL COMPLEX AND METHODS FOR ITS PREPARATION AND USE AP2M1, AP1M1, AP3M1 LPO 1530/4885BRD4 3284/4885KDM4E 3376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.